In India, we rank #6 in the CNS segment, reflecting our growing footprint in this complex therapy area.
We have a strong presence in the CNS therapy area through a diverse portfolio addressing a wide range of neurological and psychiatric conditions. Our therapies are supported by ongoing investments in research, regulatory approvals, and global collaborations. We are continuously expanding our portfolio through complex generics and targeted innovation.
In India, we rank #6 in the CNS segment, reflecting our growing footprint in this complex therapy area.
In India, we are going deeper in our existing therapy through our anti-epileptics, anti-depressants, and pain management portfolios, as well as newer therapy areas.
Platforms like SAARTHI enable better patient–doctor communication through multilingual tools that support mental health education and treatment plans.
Our state-of-the-art, neuro-rehabilitation center, Atharv Ability provides multidisciplinary rehabilitation services for patients recovering from neurological conditions such as stroke, traumatic brain injury, spinal cord injury, Parkinson’s disease, multiple sclerosis, and cerebral palsy.
Our CNS portfolio addresses multiple neurological and psychiatric conditions across different stages of disease management.
A neurological disorder characterized by recurrent seizures resulting from abnormal brain activity. Our therapies support seizure control and long-term disease management.
Mental health conditions and mood disorders affect a patient’s emotional wellbeing and in turn, their physical health. We offer treatments and awareness initiatives aimed at improving overall patient healthcare outcomes.
Chronic psychiatric conditions affect thinking, perception, and behavior of a person. Long-acting therapies and targeted treatments help support better adherence and disease stability.
Migraine and chronic headache disorders significantly affect quality of life and productivity. We provide therapies designed to reduce the frequency and severity of attacks.
Rare neuromuscular conditions such as non-dystrophic myotonia, impair muscle relaxation and movement. Specialty therapies we offer, aim to improve mobility and functional independence.
Disclaimer: The content on this website/webpage relates to a specific therapy/therapeutic area and is intended solely for informational and educational purposes for healthcare professionals and patients across India and other global locations, is not intended to substitute professional medical advice, diagnosis, or treatment. Advice from a physician or other qualified healthcare professional must be sought for any queries regarding a medical condition or treatment. Information on this website/webpage should not be solely used or relied upon in the absence of or delay in receiving professional medical advice. While Lupin makes reasonable efforts to ensure that the information is accurate and up to date, it makes no representations or warranties regarding its completeness or accuracy and accepts no liability for reliance on such information. The information on this website/webpage is not a substitute for prescribing information or patient information leaflets accompanying any medicinal product. The information on this website/webpage is subject to change without notice and may not reflect the most current medical, scientific, or regulatory developments. All content on this website/webpage is the intellectual property of Lupin and shall not be reproduced, modified, distributed, or used for any commercial purpose without the prior written consent of Lupin.
Our CNS portfolio includes therapies addressing neurological, psychiatric, and rare neuromuscular conditions across global markets.
This is for the treatment of generalized and focal epilepsy.
This is for the treatment of major depressive disorders.
This is an anti-epileptic medicine that helps treat seizures (fits) in epilepsy.
We continue to strengthen our CNS capabilities through innovation, specialty medicines, and patient support initiatives.
CNS disorders present complex clinical challenges that require long-term treatment, rehabilitation, and ongoing patient support. We at Lupin remain committed to advancing neurological care through innovative therapies, specialty medicines, and patient-focused initiatives, to help improve neurological health outcomes and overall quality of life.
